Ardelyx (ARDX)

• Market cap: $1.47B
• 1 day: -1.47%
• 5 days: 1.51%
• 1 month: 20.56%
• 3 months: 7.86%
• 6 months: 71.1%
• Year to date: 17.97%
• 1 year: 31.59%
• 5 years: 5.78%
• 10 years: -66.63%
• Sector: Healthcare
• Industry: Biotechnology

About: Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.

Employees: 395